Rapid tests (RTs) might have several advantages over standard laboratory procedures, increasing access to diagnosis, especially among vulnerable populations and/or those living in remote areas. The aim of this study was to evaluate the performance of RTs for the detection of hepatitis B virus surface antigen (HBsAg) in samples from different populations/settings. Three RTs for HBsAg detection (Vikia® HBsAg, HBsAg Teste Rápido®, and Imuno-Rápido HBsAg®) and different biological specimens (serum, whole blood, and saliva) were evaluated. Analyses comprised a reference panel and samples from field studies targeting suspected cases of hepatitis B virus (HBV) (G I), individuals living in deprived areas (G II), and highly vulnerable individuals (G III). Enzyme immunoassay (EIA) was defined as the gold standard in this study. Reproducibility, repeatability, and cross-reactivity with other infectious agents such as dengue, immunodeficiency (HIV), and hepatitis C (HCV) viruses and T. pallidum were determined. For the reference panel, the sensitivity and specificity of all HBsAg RTs were higher than 93.00 %. G I presented the highest kappa values for all rapid assays using sera samples. When using serum, the sensitivity values were higher than 93.40 for G I, 60.00 % for G II and 66.77 % for G III, and the specificity values were higher than 99.50 for GI, 97.20 for G II and 99.10 % for G III for all tests. For whole blood samples & the Vikia® HBsAg assay, the best performance was achieved for GIII (k = 79.75 %). For saliva samples, the Imuno-Rápido HBsAg® assay showed the highest concordance values with EIA for G I (40.68 %) and G II (32.20 %). The reproducibility and repeatability of all RTs for serum and saliva were excellent, and the concordance between HBsAg EIAs and RTs using samples reactive with other infectious agents varied from 70.10 % to 100.00 %. The overall performance of RTs for HBsAg in serum was high/moderately high for all groups, thereby promoting increased access to HBV diagnosis among vulnerable populations as well as samples from individuals in emergency settings or remote areas. Rapid tests for HBsAg using whole blood could be used in prevalence studies, though these assays should not be used for saliva samples.
MicroRNAs (miRNAs) can act as biomarkers and descriptors of the association between infections and other diseases, such as hepatitis and COVID-19. This study aims to investigate the role of miRNA serum expression according to laboratory data concerning hepatitis and COVID-19. Seventy individuals recruited in Southern and Southeastern Brazil donated serum samples and were divided into four groups: (i) 20 negative subjects, (ii) 20 presenting hepatitis, (iii) 19 with COVID-19 and (iv) 11 with hepatitis and COVID-19. Three miRNAs (miR-122, miR-143 and miR-223) were evaluated using real-time PCR. Hematological and biochemical markers were also analyzed. MiR-143 and miR-223 were downregulated among the hepatitis/COVID-19 group (p < 0.05). A positive correlation was observed between miR-223 and lymphocytes. There was a negative correlation between alanine transaminase (ALT) and aspartate transaminase (AST) for miR-143 and miR-223 and gamma-glutamyl transferase (GGT), alkaline phosphatase (AP) and neutrophil/lymphocyte ratio (NLR) only for miR-223 (p < 0.05). For hepatic fibrosis (FIB-4), miR-122 and miR-143 had a greater association and miR-223 was more associated with a history of vaccination against COVID-19. MicroRNAs 143 and 223 could be useful as biomarkers for hepatitis coinfection with COVID-19.
1 January 2025 in Arquivos Brasileiros de Cardiologia
Resumo Fundamento A doença hepática esteatótica associada à disfunção metabólica (DHEADM) é a enfermidade hepática mais prevalente no mundo. A DHEADM pode progredir para fibrose e complicações associadas, sendo a doença cardiovascular a principal causa de morte nesses indivíduos. Marcadores de aterosclerose carotídea são capazes de predizer desfechos cardiovasculares, o que ressalta a importância de sua associação com a fibrose hepática. Objetivo Avaliar a relação entre fibrose hepática na DHEADM e aterosclerose subclínica, por meio da análise da espessura médio-intimal da carótida (EMIC), da idade vascular (IV) e da presença de placas ateroscleróticas. Métodos Estudo prospectivo conduzido com participantes sob risco para DHEADM. A esteatose e a fibrose hepáticas foram avaliadas por ultrassonografia e elastografia hepática, com uso do parâmetro de atenuação controlada. A aterosclerose carotídea foi analisada por meio de ultrassonografia de carótidas, medições da EMIC e da IV. Adotou-se nível de significância de 5% (p < 0,05). Resultados Foram incluídos 114 participantes, com idade mediana de 64 anos (IIQ: 55–68), sendo 96 (84%) do sexo feminino. A esteatose foi identificada em 99 participantes (86,8%) e a fibrose em 31 (27,2%). Placas ateroscleróticas estavam presentes em 33 indivíduos (28,9%), sem diferença significativa na frequência entre os grupos. No entanto, o grupo com fibrose apresentou EMIC mais elevada e IV aumentada. Em uma análise de subgrupo com 85 participantes com diabetes mellitus tipo 2 (DM2), 27 (31,8%) apresentavam fibrose. Esses indivíduos apresentaram EMIC superior (0,742 mm vs. 0,653 mm; p < 0,05) e IV nove anos acima da idade cronológica, quando comparados aos indivíduos sem fibrose (p < 0,05). Conclusão Este estudo demonstra que indivíduos com DHEADM e fibrose hepática apresentam maior envelhecimento vascular e risco cardiovascular aumentado, refletidos por elevações na EMIC e na IV.
Liver Cirrhosis is currently understood as a pathological systemic process, inflammatory, vascular and, overall, dynamic and bidirectional. The intrahepatic circulation is the site of pronounced and determinant alterations characterized by the increase of mechanical resistance to the portal blood flow and the increase of the hepatic vascular tone. Compensated cirrhosis and decompensated cirrhosis can be described according to the presence and severity of portal hypertension. The most accurate method for diagnosis and stratification of portal hypertension is the measurement of the hepatic venous pressure gradient (HVPG). The standard pharmacological treatment available for cirrhotic portal hypertension consists, currently in the use of a non-selective beta-blocker(NSBB). A significant proportion of patients do not respond to treatment. Moreover, it seems to be a therapeutic window of the non-selective beta blockers in which very early stages of compensated cirrhosis and decompensated patients are not benefiting from that medication. The discovery of new drugs that might interfere in the disease’s evolution and treat portal hypertension, allows a glimpse of a new horizon in hepatic cirrhosis. HIPERTENSÃO PORTA CIRRÓTICA: NOVAS PERSPECTIVAS SOBRE UMA SÍNDROME ANTIGA RESUMO: A cirrose Hepática é, atualmente, compreendida como um processo patológico sistêmico, inflamatório, vascular e, em geral, dinâmico e bidirecional. A circulação intra-hepática é o local de alterações pronunciadas e determinantes, caracterizadas pelo aumento da resistência mecânica ao fluxo sanguíneo portal e pelo aumento do tónus vascular hepático. A cirrose compensada e a descompensada podem ser descritas de acordo com a presença e gravidade da hipertensão porta. O método mais preciso para o diagnóstico e estratificação da hipertensão porta é a medida do gradiente de pressão venosa hepática (HVPG). O tratamento farmacológico disponível para a hipertensão porta cirrótica, nos dias atuais, consiste na utilização de um beta bloqueador não seletivo (NSBB). Uma proporção significativa dos pacientes não responde ao tratamento. Além disso, parece haver uma janela terapêutica dos beta-bloqueadores não seletivos, em que fases muito iniciais da cirrose compensada e pacientes descompensados não se beneficiam da medicação. Logo, a descoberta de novas drogas que possam interferir na evolução da doença e tratar a hipertensão porta, permite vislumbrar um novo horizonte na cirrose hepática.